How much can patients, with low Karnofsky performance status and advanced non-small cell lung cancer, benefit from cisplatin-based chemotherapy? A retrospective analysis of a phase III randomised trial

Marianne Paesmans,Jean-Jacques Lafitte,Thierry Berghmans,J. Lecomte,Constantinos Alexopoulos,O Van Cutsem,Vicente Giner,Anna Efremidis,M.C. Berchier,Jean-Paul Sculier

How much can patients, with low Karnofsky performance status and advanced non-small cell lung cancer, benefit from cisplatin-based chemotherapy? A retrospective analysis of a phase III randomised trial

2007

Marianne Paesmans
Jean-Jacques Lafitte
Thierry Berghmans
J. Lecomte
Constantinos Alexopoulos
O Van Cutsem
Vicente Giner
Anna Efremidis
M.C. Berchier
Jean-Paul Sculier

19516 Background: Performance status (PS) is a strong independent prognostic factor for survival in patients with advanced non- small cell lung cancer and administration of platinum-based chemother...

Keywords:

Karnofsky Performance Status
Cell
Cisplatin
Oncology
Chemotherapy
Lung cancer
Medicine
Internal medicine
non small cell
retrospective analysis
cisplatin based chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations